Compare EKSO & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EKSO | LGVN |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 34.0M |
| IPO Year | 2012 | 2021 |
| Metric | EKSO | LGVN |
|---|---|---|
| Price | $11.80 | $0.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9.50 | $3.00 |
| AVG Volume (30 Days) | 55.1K | ★ 383.9K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.76 | ★ 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | $81.23 | N/A |
| Revenue Next Year | $7.29 | $10.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.88 | $0.48 |
| 52 Week High | $13.50 | $1.80 |
| Indicator | EKSO | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 60.17 | 44.67 |
| Support Level | $8.30 | $0.74 |
| Resistance Level | $12.39 | $0.86 |
| Average True Range (ATR) | 0.86 | 0.07 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 79.44 | 49.28 |
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.